During September 2 to 7, the 2021 China International Fair for Trade in Services (CIFTIS) co-sponsored by the Ministry of Commerce and the Beijing Municipal Government was held in Beijing. In the service demonstration case selection, Shanghai Medicilon Inc. (Medicilon) “Internet + One-Stop Preclinical R&D Service Platform” was awarded the “Science and Technology Innovation Service Demonstration Case” award.
It is reported that the “Science and Technology Innovation Service Demonstration Case” award of the CIFTIS aims to commend the creative application of new knowledge and new technology in the field of service, especially the field of digital economy, through independent innovation and research and development to effectively promote industrial upgrading and development.
Innovating with the times in continuous search, and innovating technology in continuous research and development, Medicilon has gone through 17 years of hard work, followed the development of science and technology, and integrated the Internet with international advanced drug development technology to build an “Internet + One-Stop Preclinical R&D Service Platform”, which accomplishes the integration of experimental data collection and analysis in the process of new drug R&D. Adopting the roadmap of system construction, self-evaluation, improvement, and continuous optimization to strengthen the overall management level of the enterprise, and improve the quality control ability through the unique “a set of systems, a mechanism, and a project” operation mode, so that the drug research and development process is safer and more scientific.
Medicilon’s “Internet + One-Stop Preclinical R&D Service Platform” won the “Science and Science and Technology Innovation Service Demonstration Case” award. It demonstrates Medicilon’s profound new drug research and development background and excellent quality management system, as well as its leading advantage in biopharmaceutical industry. It also recognizes and affirms Medicilon’s empowerment of global partners in the research and development of new drugs.
Dr. Chunlin Chen, Founder & CEO of Medicilon, said, “Innovation is an important driving force for Medicilon’s development, and it is also a core competitiveness. In the future, Medicilon will continue to explore cutting-edge technological breakthroughs in technology, continue to innovate R&D service platforms, meet the unmet needs of new drug drug R&D from patients around the world, and help to accomplish the grand blueprint of ‘Healthy China 2030’ at an early date.”